OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment
OrthoSpineNews
JANUARY 29, 2025
The designation covers the use of the therapeutic medical device to treat patients who continue to experience knee pain or impairment following a meniscus surgery, which impacts approximately 250,000 Americans annually. ” OrthoPreserve hopes to launch their Pilot clinical trial in 2026, while aiming for potential FDA approval by 2029.
52 
Let's personalize your content